{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'recommended to be hormonal, such as an oral contraceptive. Hormonal contraception', 'must be in use for at least one full cycle prior to Baseline. Highly effective contraceptive', 'methods (with a failure rate less than 1% per year), when used consistently and correctly,', 'includes implants, injectables, combined oral contraceptives, some intrauterine devices', '(IUDs), sexual abstinence or vasectomized partner.', '9. Male subjects must be surgically sterile or, if sexually active with a female partner of', 'childbearing potential, must agree to use a barrier contraceptive method from Baseline', 'through 180 days after the last dose of study drug.', '10. Subject is willing and able to comply with the prescribed treatment protocol and', 'evaluations for the duration of the study.', '11. Has not received any treatment for TED since Week 24 of the HZNP-TEP-301 study.', '9.3.2 Exclusion Criteria', '1. Subjects will be ineligible if, in the opinion of the Investigator, they are unlikely to', 'comply with the study protocol or have a concomitant disease or condition that could', 'interfere with the conduct of the study or potentially put the subject at unacceptable risk.', 'The exclusion criteria (except those related to screening) of protocol HZNP-TEP-301 also apply', 'to this open-label extension study.', '9.3.3 Removal of Subjects from Therapy or Assessment', 'All subjects are free to withdraw from study participation at any time, for any reason, and', 'without prejudice to their further medical care. In addition, the Investigator may terminate a', 'subject from the study at any time. The primary reason for discontinuation from the study and/or', 'study drug should be recorded on the eCRF using one of the following categories:', 'Adverse Event. The subject experiences an AE that imposes an unacceptable risk to the', \"subject's health, or the subject is unwilling to continue because of an AE. AEs requiring\", 'permanent study drug discontinuation per the protocol include:', 'A drug-related anaphylactic reaction.', 'A persistently severe drug-related AE that does not abate to mild or moderate', 'intensity at least 2 weeks prior to the next scheduled dose.', 'Severe drug-related hyperglycemia (e.g., blood glucose > 250 mg/dL) that does', 'not abate to mild or moderate intensity with anti-diabetic treatment (dose may be', 'skipped up to 2 times prior to permanently discontinuing study drug; see', 'Section 9.4.6.3.2 for details).', 'Diagnosed or suspected IBD (e.g., diarrhea with or without blood or rectal', 'bleeding associated with abdominal pain or cramping/colic, urgency, tenesmus, or', 'incontinence for more than 4 weeks without a confirmed alternative diagnosis OR', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 73 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'endoscopic or radiologic evidence of enteritis/colitis without a confirmed', 'alternative diagnosis).', 'Lack of Efficacy. Removal of a subject from the study is at the discretion of the', 'Investigator and may occur if the Investigator determines that study drug administration', 'is not benefitting the subject and eye symptoms linked to progressing disease worsen', 'posing an unacceptable risk to the subject. The specific care of the subject is best', \"determined by the Investigator and managing physician(s) involved in the subject's care\", 'and may require removal from the study. All subjects are free to withdraw from study', 'participation at any time, for any reason, allowing them to receive any specific treatment', 'for TED that is considered necessary per their treating physician and local standard of', 'care.', 'Non-Compliance with Study Drug/Other/Protoco Deviations. The subject has a', 'significant protocol deviation, does not comply with study drug administration schedule,', 'or fails to adhere to other study requirements as stated in the protocol.', 'Lost to Follow-Up. The subject does not return to the clinic for scheduled assessments,', \"and does not respond to the site's attempts to contact the subject.\", 'Voluntary Withdrawal. The subject wishes to withdraw from the study. The clinical site', 'should attempt to determine the underlying reason for the voluntary withdrawal and', 'document it on the eCRF; if the underlying reason is documented as an AE or lack of', 'efficacy, the category of withdrawal should be marked in the corresponding category and', 'not as voluntary withdrawal.', 'Study Terminated by Sponsor. The Sponsor, IRB/IEC, or regulatory agency terminates', 'the study.', 'Pregnancy.', 'When treatment is complete, subjects will undergo the scheduled Week 24 assessments.', 'Subjects who were proptosis non-responders in HZNP-TEP-301 will participate in the', 'Follow-Up Period. Subjects who enter the Follow-Up Period but prematurely discontinue study', 'participation prior to Month 12 will return for a final visit and undergo the scheduled Month 12', 'assessments prior to study discharge. Subjects who discontinue due to an AE should be followed', 'until resolution or stabilization of the AE, or an adequate explanation for the event is obtained.', 'Subjects who relapsed during the HZNP-TEP-301 study will not participate in the Follow-up', 'Period.', 'Subjects who complete the study (Month 12 Visit for proptosis non-responders in Study HZNP-', 'TEP-301 and Week 24 Visit for subjects who relapsed during the Follow-up Period in Study', 'HZNP-TEP-301) will be contacted 6 and 12 months after the last visit via phone or email by', 'research staff to enquire if any treatment for TED has been received since last study contact.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 74 of 118']\n\n###\n\n", "completion": "END"}